| Dr Rebecca E Barcelow, OD | |
|
1593 Vermont Route 107, Bethel, VT 05032-4456 | |
| (802) 235-9728 | |
| Not Available |
| Full Name | Dr Rebecca E Barcelow |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 12 Years |
| Location | 1593 Vermont Route 107, Bethel, Vermont |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902233760 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 030.0099063 (Vermont) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eyecare For You Pc | 5799001822 | 6 |
| Junction Eye Center Llc | 1951664721 | 5 |
News Archive
Antibe Therapeutics Inc. announces that it has granted its directors, officers and employees options to purchase a total of 9,496,000 common shares of Antibe pursuant to the Company's stock option plan.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today publication of Reproductive Health Matters' 2012 supplement issue "Pregnancy decisions of women living with HIV".
The biopharmaceutical company Antisense Pharma announced today that the US-American Food and Drug Administration (FDA) has issued an Investigational New Drug (IND)-authorisation for clinical studies with trabedersen for patients with high-grade glioma. This authorisation entitles the company to include US-American clinics both in the phase III study SAPPHIRE and in further studies.
BioDelivery Sciences International, Inc. today announced a positive meeting with the U.S. Food and Drug Administration (FDA), Meda and BDSI that occurred on Wednesday, July 21, 2010 to discuss significant modifications to the existing Risk Evaluation and Mitigation Strategy (REMS) program for ONSOLIS (fentanyl buccal soluble film).
Physicians using Greenway Medical Technologies' electronic health record (EHR) solution, PrimeSuite, now have access to lab results, radiology reports and transcribed documents from their community health system through RelayHealth's Virtual Information Exchange platform.
› Verified 9 days ago
| Provider Name | Francis L Pinard Od Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1053589374 PECOS PAC ID: 6709092596 Enrollment ID: O20130927000604 |
News Archive
Antibe Therapeutics Inc. announces that it has granted its directors, officers and employees options to purchase a total of 9,496,000 common shares of Antibe pursuant to the Company's stock option plan.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today publication of Reproductive Health Matters' 2012 supplement issue "Pregnancy decisions of women living with HIV".
The biopharmaceutical company Antisense Pharma announced today that the US-American Food and Drug Administration (FDA) has issued an Investigational New Drug (IND)-authorisation for clinical studies with trabedersen for patients with high-grade glioma. This authorisation entitles the company to include US-American clinics both in the phase III study SAPPHIRE and in further studies.
BioDelivery Sciences International, Inc. today announced a positive meeting with the U.S. Food and Drug Administration (FDA), Meda and BDSI that occurred on Wednesday, July 21, 2010 to discuss significant modifications to the existing Risk Evaluation and Mitigation Strategy (REMS) program for ONSOLIS (fentanyl buccal soluble film).
Physicians using Greenway Medical Technologies' electronic health record (EHR) solution, PrimeSuite, now have access to lab results, radiology reports and transcribed documents from their community health system through RelayHealth's Virtual Information Exchange platform.
› Verified 9 days ago
| Provider Name | Eyecare For You Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1518296748 PECOS PAC ID: 5799001822 Enrollment ID: O20150306001311 |
News Archive
Antibe Therapeutics Inc. announces that it has granted its directors, officers and employees options to purchase a total of 9,496,000 common shares of Antibe pursuant to the Company's stock option plan.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today publication of Reproductive Health Matters' 2012 supplement issue "Pregnancy decisions of women living with HIV".
The biopharmaceutical company Antisense Pharma announced today that the US-American Food and Drug Administration (FDA) has issued an Investigational New Drug (IND)-authorisation for clinical studies with trabedersen for patients with high-grade glioma. This authorisation entitles the company to include US-American clinics both in the phase III study SAPPHIRE and in further studies.
BioDelivery Sciences International, Inc. today announced a positive meeting with the U.S. Food and Drug Administration (FDA), Meda and BDSI that occurred on Wednesday, July 21, 2010 to discuss significant modifications to the existing Risk Evaluation and Mitigation Strategy (REMS) program for ONSOLIS (fentanyl buccal soluble film).
Physicians using Greenway Medical Technologies' electronic health record (EHR) solution, PrimeSuite, now have access to lab results, radiology reports and transcribed documents from their community health system through RelayHealth's Virtual Information Exchange platform.
› Verified 9 days ago
| Provider Name | Junction Eye Center Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1841790326 PECOS PAC ID: 1951664721 Enrollment ID: O20180409000194 |
News Archive
Antibe Therapeutics Inc. announces that it has granted its directors, officers and employees options to purchase a total of 9,496,000 common shares of Antibe pursuant to the Company's stock option plan.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today publication of Reproductive Health Matters' 2012 supplement issue "Pregnancy decisions of women living with HIV".
The biopharmaceutical company Antisense Pharma announced today that the US-American Food and Drug Administration (FDA) has issued an Investigational New Drug (IND)-authorisation for clinical studies with trabedersen for patients with high-grade glioma. This authorisation entitles the company to include US-American clinics both in the phase III study SAPPHIRE and in further studies.
BioDelivery Sciences International, Inc. today announced a positive meeting with the U.S. Food and Drug Administration (FDA), Meda and BDSI that occurred on Wednesday, July 21, 2010 to discuss significant modifications to the existing Risk Evaluation and Mitigation Strategy (REMS) program for ONSOLIS (fentanyl buccal soluble film).
Physicians using Greenway Medical Technologies' electronic health record (EHR) solution, PrimeSuite, now have access to lab results, radiology reports and transcribed documents from their community health system through RelayHealth's Virtual Information Exchange platform.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rebecca E Barcelow, OD 1593 Vermont Route 107, Bethel, VT 05032-4456 Ph: (802) 235-9728 | Dr Rebecca E Barcelow, OD 1593 Vermont Route 107, Bethel, VT 05032-4456 Ph: (802) 235-9728 |
News Archive
Antibe Therapeutics Inc. announces that it has granted its directors, officers and employees options to purchase a total of 9,496,000 common shares of Antibe pursuant to the Company's stock option plan.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today publication of Reproductive Health Matters' 2012 supplement issue "Pregnancy decisions of women living with HIV".
The biopharmaceutical company Antisense Pharma announced today that the US-American Food and Drug Administration (FDA) has issued an Investigational New Drug (IND)-authorisation for clinical studies with trabedersen for patients with high-grade glioma. This authorisation entitles the company to include US-American clinics both in the phase III study SAPPHIRE and in further studies.
BioDelivery Sciences International, Inc. today announced a positive meeting with the U.S. Food and Drug Administration (FDA), Meda and BDSI that occurred on Wednesday, July 21, 2010 to discuss significant modifications to the existing Risk Evaluation and Mitigation Strategy (REMS) program for ONSOLIS (fentanyl buccal soluble film).
Physicians using Greenway Medical Technologies' electronic health record (EHR) solution, PrimeSuite, now have access to lab results, radiology reports and transcribed documents from their community health system through RelayHealth's Virtual Information Exchange platform.
› Verified 9 days ago
Dr. Luben Metodiev Ikonomov, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 1593 Vermont Route 107, Bethel, VT 05032 Phone: 802-234-9728 Fax: 802-234-9728 | |
Eyecare For You, Pc Optometrist Medicare: Medicare Enrolled Practice Location: 1593 Vt Rt 107, Bethel, VT 05032 Phone: 802-234-9728 Fax: 802-234-9732 | |
Jerry Albert Barcelow, Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1593 Vt Rte 107, Bethel, VT 05032 Phone: 802-234-9728 Fax: 802-234-9732 | |
Dr. Dean A Barcelow, O.D. Optometrist Medicare: May Accept Medicare Assignments Practice Location: 1593 Vermont Route 107, Bethel, VT 05032 Phone: 802-234-9728 Fax: 802-234-9732 |